Evidence map›Paper›PMID 25502526›Full record

ArticleJournal of clinical microbiology2015

Identification and susceptibility of Aspergillus section nigri in china: prevalence of species and paradoxical growth in response to echinocandins.

Yali Li, Zhe Wan, Wei Liu, Ruoyu Li

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Epidemiological Characteristics of ClinicalJournal of fungi (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Molecular Identification ofInfection and drug resistance · 2025
    Article
  6. Article
  7. Chitin Biosynthesis inJournal of fungi (Basel, Switzerland) · 2023
    Review
  8. Poly-(lactic-Molecules (Basel, Switzerland) · 2022
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Infection and drug resistance · 2020
    Article
  16. Review
  17. Article
  18. Epidemiology of fungal infections in China.Frontiers of medicine · 2018
    Review
  19. Drug Sensitivity and Resistance Mechanism in Aspergillus SectionAntimicrobial agents and chemotherapy · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yali LiDepartment of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, and Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Beijing, People's Republic of China.
Zhe WanDepartment of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, and Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Beijing, People's Republic of China.
Wei LiuDepartment of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, and Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Beijing, People's Republic of China.
Ruoyu LiDepartment of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, and Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, Beijing, People's Republic of China mycolab@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular identification and in vitro antifungal susceptibility tests of 43 Aspergillus section Nigri isolates from China were performed. Aspergillus niger and Aspergillus tubingensis were present in almost equal numbers. All of the isolates had low MIC/MECs (minimum effective concentrations) for the 7 common antifungals, and a paradoxical effect was observed for the first time in response to caspofungin and micafungin.

Indexed as

Antifungal AgentsAspergillosisAspergillusChinaEchinocandinsHumansMicrobial Sensitivity TestsPrevalenceAntifungal AgentsEchinocandins

Identifiers

PMID25502526
PMCPMC4298494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.